Amphastar announces buyback of 26% of the equity in its anp subsidiary and spin-off its hanxin subsidiary

Rancho cucamonga, calif., may 07, 2021 (globe newswire) -- amphastar pharmaceuticals, inc. (nasdaq: amph) announced the restructuring of its chinese subsidiaries, primarily amphastar nanjing pharmaceuticals inc. (“anp”). as part of the restructuring, amphastar will buyback 26% of anp's equity currently held by third parties. in addition, anp will spin-off its chinese subsidiary, nanjing hanxin pharmaceutical technology co., ltd. and hanxin's subsidiaries (collectively, “hanxin”). the restructuring is subject to regulatory approval, and the total cash payment by amphastar for this restructuring will be approximately $29 million.
AMPH Ratings Summary
AMPH Quant Ranking